Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of oral IW-9179 in functional dyspepsia
NL-OMON36972Phase 2Not yet recruiting
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recanaclotide in functional dyspepsia (FD) (4 arms), sponsored by Ironwood Pharmaceuticals. Primary endpoints: Post-meal Symptom Severity assessment, Daily Patient Symptom Severity assessment and 2 more. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
recanaclotide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NL-OMON36972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36972.